Showing results (1-10 of 71) with videos related to
Sort By:
Pageof 8
Clinical and Experimental Immunology|October 25, 2007
A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiencyC G M KallenbergJournal of Autoimmunity|December 29, 2007
Pathogenesis of PR3-ANCA associated vasculitisC G M KallenbergClinical and Experimental Immunology|March 31, 2011
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go?C G M KallenbergClinical and Experimental Rheumatology|August 4, 2009
New advances in the pathogenesis of ANCA-associated vasculitidesM Chen, C G M KallenbergClinical Rheumatology|June 28, 2002
Familial occurrence of autoimmune diseases and autoantibodies in a Caucasian population of patients with systemic lupus erythematosusS Corporaal, M Bijl, C G M KallenbergCurrent Medicinal Chemistry|March 11, 2010
Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implicationsJohanna Westra, Grietje Molema, C G M KallenbergRheumatology (Oxford, England)|March 7, 2008
Macrovascular disease and atherosclerosis in SScM E Hettema, H Bootsma, C G M KallenbergThe Netherlands Journal of Medicine|February 18, 2011
Vaccination of the immune-compromised patients with focus on patients with autoimmune-inflammatory diseasesM Bijl, C G M Kallenberg, S van AssenAutoimmunity|October 9, 2009
Role of CCR5 Delta32 bp deletion in RA and SLEH A Martens, C G M Kallenberg, M BijlLupus|May 13, 2009
Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?S Dolff, W H Abdulahad, M Bijl, et al.Pageof 8